Bock E L, Fülle H H, Heimpel H, Pribilla W
Med Klin. 1976 Mar 26;71(13):539-47.
A controlled randomized multicenter trial was carried out to examine the therapeutic value of the androgen mesterolone in aplastic anemia and anemia of renal failure. the drug was given in a dose of 2 mg/kg orally for 6 months. Control patients received no androgens but were otherwise similarily treated. 31 patients with aplastic anemia could be evaluated. No significant difference was found between androgen treated control cases in respect to bone marrow cellularity, improvement of peripheral blood cell counts or survival. In a group of 14 patients not being hemodialyzed with anemia from renal failure, 3 of the androgen treated and none of the control patients showed progressive and significant improvement of erythropoiesis; however, this was not a statistically significant difference when the both groups of patients were compared. The results do not suggest that the androgen mesterolone is of therapeutic value in the majority of adult patients with aplastic anemia. Possible reasons of the discrepancy to positive results reported in the literature are discussed.
开展了一项对照随机多中心试验，以研究雄激素美睾酮在再生障碍性贫血和肾衰竭贫血中的治疗价值。药物以2mg/kg的剂量口服给药，持续6个月。对照患者未接受雄激素治疗，但在其他方面接受类似治疗。31例再生障碍性贫血患者可进行评估。在骨髓细胞计数、外周血细胞计数改善或生存率方面，雄激素治疗组与对照组之间未发现显著差异。在一组14例未进行血液透析的肾衰竭贫血患者中，3例接受雄激素治疗的患者红细胞生成有进行性显著改善，而对照组患者均无此情况；然而，两组患者比较时，这一差异无统计学意义。结果并不表明美睾酮对大多数成年再生障碍性贫血患者具有治疗价值。文中讨论了与文献报道的阳性结果存在差异的可能原因。
